Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Preach It, Brother | Main | Cox-2 Confusion »

October 19, 2004

Epidemic of Good Sense Spreading, Scientists Say

Email This Entry

Posted by Derek

Thanks to the Red Sox and the Cardinals, I'm pressed for blogging time today. But I wanted to point out an article by Malcolm Gladwell that was just posted at the New Yorker site. Entitled "Don't Blame Big Pharma", it's a look at Marcia Angell's book - with which he's not impressed - and at the drug pricing issue in general. It contains indisputably sensible stuff like the following, regarding the prices of prescription versus generic drugs:

"It is not accurate to say, then, that the United States has higher prescription-drug prices than other countries. It is accurate to say only that the United States has a different pricing system from that of other countries. Americans pay more for drugs when they first come out and less as the drugs get older, while the rest of the world pays less in the beginning and more later. Whose pricing system is cheaper? It depends. . ."

I think Gladwell's key point is this one, and it's well worth thinking about:

"The core problem in bringing drug spending under control, in other words, is persuading the users and buyers and prescribers of drugs to behave rationally, and the reason we’re in the mess we’re in is that, so far, we simply haven’t done a very good job of that."

Of course, that would mean that a good part of my industry's profits might well be made through the suboptimal decisions of its customers - not that we we'd be alone in that category, for sure. But it's not a group I feel comfortable being a member of, and I'd rather we found a way out of it. More thoughts on this to come.

Comments (4) + TrackBacks (0) | Category:


COMMENTS

1. Paul on October 19, 2004 10:12 AM writes...

The above is not necessarily true though.

Everybody wants the best for themselves, and wants someone else to pay. Why take Zantac when your insurance plan pays for Nexium? Who cares if it only works a little better at 20 times the cost? Why should an MD prescribe Zantac instead of Nexium when some lawyer will trash him for not using a newer, marginally more effective medication?

Vioxx (R.I.P.)/Celebrex/Bextra are no more efficacious than Motrin, and only safer in those who do not take aspirin, or prone to GI bleeding.

Why, then, are millions of people taking these medications? Same reasons - insurance pays the difference so the patient doesnt care, and doctors live in fear that one of their patients will sue for a GI bleed that may or may not be caused by medication.

Permalink to Comment

2. Derek Lowe on October 19, 2004 11:40 AM writes...

Free, you're going to have to convince me that your comment isn't an ad for your associated web site. Explain what, exactly, you mean by "linking arms" and "not buying expensive meds". Make it good, make it interesting, and no ads, please.

Permalink to Comment

3. Clay on October 19, 2004 2:08 PM writes...

I never read Angell's book, but I read her essay in the New York REview of Books. Gladwell's response, to my mind, puts her argument--warped by the heat of her self-righteous indignation--into the garbage can. Several months ago, who could have expected such a rational voice in such a prominent publication?

Permalink to Comment

4. jeet on October 19, 2004 4:32 PM writes...

fear of lawsuits is a problem, however most of the docs I talk to tell me that they just give the patient what they want (in terms of brand) so that they can move on.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought